Journal
CURRENT ATHEROSCLEROSIS REPORTS
Volume 18, Issue 10, Pages -Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-016-0614-1
Keywords
apoC-III; Lipoproteins; Triglycerides; Remnants; CVD
Categories
Funding
- Amgen
- AstraZeneca
- Chiesi Pharma
- Sanofi Aventis
- Novo Nordisk
- Merck Sharp Dohme
- Sanofi-Aventis
Ask authors/readers for more resources
ApoC-III was discovered almost 50 years ago, but for many years, it did not attract much attention. However, as epidemiological and Mendelian randomization studies have associated apoC-III with low levels of triglycerides and decreased incidence of cardiovascular disease (CVD), it has emerged as a novel and potentially powerful therapeutic approach to managing dyslipidemia and CVD risk. The atherogenicity of apoC-III has been attributed to both direct lipoprotein lipase-mediated mechanisms and indirect mechanisms, such as promoting secretion of triglyceride-rich lipoproteins (TRLs), provoking proinflammatory responses in vascular cells and impairing LPL-independent hepatic clearance of TRL remnants. Encouraging results from clinical trials using antisense oligonucleotide, which selectively inhibits apoC-III, indicate that modulating apoC-III may be a potent therapeutic approach to managing dyslipidemia and cardiovascular disease risk.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available